Bank of New York Mellon Corp Has $3.93 Million Holdings in ImmunityBio, Inc. (NASDAQ:IBRX)

Bank of New York Mellon Corp boosted its position in shares of ImmunityBio, Inc. (NASDAQ:IBRX) by 37.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 621,536 shares of the company’s stock after acquiring an additional 170,742 shares during the period. Bank of New York Mellon Corp owned 0.09% of ImmunityBio worth $3,928,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of IBRX. Meridian Management Co. acquired a new position in shares of ImmunityBio during the 4th quarter worth about $46,000. Private Advisor Group LLC acquired a new position in shares of ImmunityBio during the fourth quarter worth approximately $53,000. Simplicity Wealth LLC acquired a new position in shares of ImmunityBio during the first quarter worth approximately $58,000. Bleakley Financial Group LLC bought a new stake in shares of ImmunityBio in the first quarter valued at approximately $58,000. Finally, Lazard Asset Management LLC increased its position in ImmunityBio by 102.6% during the first quarter. Lazard Asset Management LLC now owns 13,019 shares of the company’s stock worth $68,000 after acquiring an additional 6,593 shares during the period. Institutional investors and hedge funds own 8.58% of the company’s stock.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $3.58 on Friday. ImmunityBio, Inc. has a twelve month low of $1.25 and a twelve month high of $10.53. The stock has a market cap of $2.49 billion, a PE ratio of -3.28 and a beta of 1.02. The firm has a 50-day simple moving average of $4.71 and a 200 day simple moving average of $5.70.

ImmunityBio (NASDAQ:IBRX) last announced its quarterly earnings data on Monday, August 12th. The company reported ($0.20) EPS for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.05 million during the quarter, compared to the consensus estimate of $2.53 million. Research analysts forecast that ImmunityBio, Inc. will post -0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler reduced their price target on shares of ImmunityBio from $6.00 to $4.75 and set a “neutral” rating for the company in a report on Monday, August 19th.

ImmunityBio Company Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.